|
Essen, December 16, 2025
Brenntag, the global market leader in chemicals and ingredients distribution, today announced a new strategic partnership with Seqens for the distribution of non-GMP intermediates in Europe. High-quality products are a cornerstone of the pharmaceutical industry. At every stage of chemical synthesis—whether introducing a functional group, performing a coupling reaction, or modifying a molecular structure—the need for perfectly aligned intermediates, both in terms of quality and documentation, remains absolutely critical. This sole distribution agreement allows Brenntag to provide these high-quality intermediates from a well-known Global CDMO and ingredient manufacturer to a broad customer base, helping to optimize their way of synthesis. Seqens offers a reliable and competitive solution for customers’ non-GMP intermediate needs, while optimizing lead times and flexibility. Brenntag customers can benefit from regulatory depth, quality, flexibility, global reliability, and a secure supply chain with production in Europe. This partnership will deliver improved availability of non-GMP pharmaceutical intermediates and expanded coverage in Europe through Brenntag’s logistics and commercial expertise. Joakim Rehné, Regional President Brenntag Pharma EMEA says: “Our partnership with Seqens for intermediates marks a milestone in Brenntag’s commitment to the Pharma industry. By expanding our portfolio with these high-quality intermediates, we support our customers in all steps of their research phase. Gaining the Seqens expertise and strong team in our network of partners is a wonderful addition and we look forward to driving growth and future projects together.” Alexandra Ngawa Zenang, Business Line Manager Pharma at Sequens, adds: “This partnership is part of our strategy to stay close to our customers and reinforce our presence in the European market. It enables us to respond quickly to market demands while maintaining our high standards of quality and safety.”
About Seqens: Sequens is a global partner in health, personal care and specialty ingredients. We empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, we leverage a worldwide manufacturing network of 15 manufacturing sites and 9 state-of-the-art R&D centers in 9 countries. As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. We innovate, develop and industrialize the most demanding molecules, and implement the best available technologies. Learn more at www.seqens.com About Brenntag: Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 18,100 employees worldwide and operates a network of around 600 sites in more than 70 countries. In 2024, Brenntag generated sales of 16.2 billion EUR. The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a diversified and broad portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries. Brenntag pursues an ambitious sustainability agenda and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed at the Frankfurt Stock Exchange since 2010, in the DAX since September 2021. In addition, the Brenntag SE shares are listed in the DAX 30 ESG and DAX ESG Target. For more information, visit www.brenntag.com.
|
